Skip to main content
Publications
Mellott CE, Jaworski R, Carrico J , Talbird SE , Dobrowolska I, Golicki D, Bencina G, Clinkscales M, Karamousouli E, Eiden AL, Sabale U. Public health impact and return on investment of the pediatric immunization program in Poland . Expert Rev Vaccines. 2023 Dec;22(11):1114-25. doi: 10.1080/14760584.2023.2275712
Barbieri M, Senese F, Mellott CE, Boccalini S, Carrico J , Bechini A, Talbird SE , Chen Y-H, Bencina G. Public health impact and return on investment of the pediatric national immunization program in Italy . Presented at the Italian Society of Hygiene, Preventive Medicine, and Public Health Conference; October 12, 2023. Cernobbio, Italy.
Carrico J , Mellott CE, Talbird SE , Bento-Abreu A, Merckx B, Vandenhaute J, Benchabane D, Dauby N, Ethgen O, Lepage P, Luyten J, Raes M, Simoens S, Van Ranst M, Eiden A, Nyaku MK, Bencina G. Public health impact and return on investment of Belgium's pediatric immunization program . Front Public Health. 2023 Jun 22;11:1032385. doi: 10.3389/fpubh.2023.1032385
Perdrizet J, Horn EK, Hayford K, Grant L, Barry R, Huang L, McDade C , Wilson M . Historical population-level impact of infant 13-valent pneumococcal conjugate vaccine (PCV13) national immunization programs on invasive pneumococcal disease in Australia, Canada, England & Wales, Israel, and the United States . Infect Dis Ther. 2023 May;12(5):1351-64. doi: 10.1007/s40121-023-00798-x
Mellott C, Jaworski R, Carrico J , Clinkscales M, Talbird S , Dobrowolska I, Golicki D, Tsoumani E, Sabale U. Public health impact and return on investment of the pediatric immunization program in Poland . Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S117. doi: 10.1016/j.jval.2022.09.568
Talbird S , Graham J , Anderson S , Nossov M, Beattie N, Lains Sousa C, Rak A, Masters III H, Diaz-Mitoma F. Health and economic impact of a novel 3-antigen vaccine for the prevention of hepatitis B in adults in Germany: a cost-effectiveness analysis . Poster presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S135. doi: 10.1016/j.jval.2022.09.649
Talbird S , Graham J , Anderson S , Nossov M, Beattie N, Lains Sousa C, Rak A, Masters III H, Diaz-Mitoma F. Cost-effectiveness and epidemiological impact of a novel 3-antigen vaccine for the prevention of Hepatitis B in adults in the United Kingdom . Poster presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria. doi: 10.1016/j.jval.2022.09.782
Perdrizet J, Horn EK, Hayford K, Grant L, Barry R, Huang L, McDade C , Wilson M . Estimating the historical population-level impact of PCV13 national immunization programs on invasive pneumococcal disease in Australia, Canada, Israel, England & Wales, and the United States . Poster presented at the ISPPD-12 (International Society of Pneumonia and Pneumococcal Diseases); June 19, 2022. Toronto, Canada.
Perdrizet J, Horn EK, Hayford K, Grant L, Barry R, Huang L, McDade C , Wilson M . Non-vaccine serotype population-level trends for invasive pneumococcal disease in Australia, Canada, Israel, England & Wales, and the United States . Poster presented at the ISPPD-12 (International Society of Pneumonia and Pneumococcal Diseases); June 19, 2022. Toronto, Canada.
Carrico J , Mellott C, Talbird S , Abreu A, Merckx B, Vanderhaute J, Benchabane D, Dauby N, Ethgen O, Lepage P, Luyten J, Raes M, Simoens S, Van Ranst M, Bencina G, Nyaku MK. Economic evaluation of the pediatric immunization program in Belgium . Poster presented at the Virtual ISPOR Europe 2021; November 30, 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.